Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many irritation/skin-side-effect and application/usage-behavior statements appear to be consistent with typical topical retinoid counseling, but the provided FDA label excerpts in the prompt only clearly support pregnancy/fetal risk content. Most non-pregnancy claims cannot be confirmed as supported by the supplied label text and are therefore treated as unsupported. Pregnancy-related claims are supported/consistent with the contraindication and fetal risk warnings described in the excerpts.
Category Scores
Accurate Statements
Fabior is a topical retinoid.
Label excerpts provided include pregnancy/fetal risk and do not explicitly mention 'topical retinoid' in the shown text; therefore support is not confirmable from provided excerpts. (No confirmed support available in supplied excerpts.)
Tazarotene can be harmful to a developing fetus.
Section 4/5.1: 'FABIOR Foam may cause fetal harm when administered to a pregnant woman' and teratogenicity language.
Fabior is contraindicated in pregnancy.
Section 4: 'FABIOR Foam is contraindicated in pregnancy.'
If pregnant, trying to become pregnant, or could become pregnant, Fabior should not be used unless a prescriber has explicitly determined it is appropriate and pregnancy prevention guidance is followed.
Section 8.1: 'FABIOR Foam is contraindicated in females who are or may become pregnant' and counseling to use contraception and stop medication if pregnancy occurs (Sections 5.1/8.1/17).
Stop using Fabior and seek medical help if symptoms suggest an allergic reaction.
Not supported: provided excerpts do not include hypersensitivity/allergic reaction counseling.
Unsupported Statements
Fabior commonly causes skin-related side effects, especially when starting treatment or if it irritates the skin.
Provided label excerpts do not include general frequency/timing language about skin side effects.
Reported Fabior side effects at the application site include burning.
Provided label excerpts do not list application-site adverse reactions.
Reported Fabior side effects at the application site include redness.
Provided label excerpts do not list application-site adverse reactions.
Reported Fabior side effects at the application site include itching.
Provided label excerpts do not list application-site adverse reactions.
Reported Fabior side effects at the application site include dryness.
Provided label excerpts do not list application-site adverse reactions.
Common Fabior application-site reactions include dryness and peeling.
Provided label excerpts do not list application-site adverse reactions.
Common Fabior application-site reactions include irritation or discomfort where it is applied.
Provided label excerpts do not list application-site adverse reactions.
Common Fabior application-site reactions include burning or stinging.
Provided label excerpts do not list application-site adverse reactions.
Fabior can cause redness.
Provided label excerpts do not list adverse reactions such as redness.
Stop using Fabior and seek medical help if intense swelling, blistering, or severe worsening rash occurs.
Provided label excerpts do not include instructions for swelling/blistering/severe worsening rash.
Seek care if irritation becomes severe or spreads beyond the treated area.
Provided label excerpts do not include such guidance.
Fabior is a topical retinoid.
Provided label excerpts provided in prompt focus on pregnancy/fetal risk and do not confirm this wording.
Using more than directed with Fabior can increase irritation.
Provided label excerpts provided do not include dosing/overuse guidance.
Applying Fabior to areas not meant for treatment can increase irritation.
Provided label excerpts provided do not include application-area limitations.
Avoid applying Fabior to broken or eczematous skin.
Provided label excerpts provided do not include this instruction.
Avoid applying Fabior to eyes, lips, corners of the nose, or other mucous membranes.
Provided label excerpts provided do not include this instruction.
Avoid applying Fabior to cuts or sunburned skin.
Provided label excerpts provided do not include this instruction.
Topical retinoids, including tazarotene, can cause an initial irritation phase early in treatment.
Provided label excerpts provided do not include early-treatment irritation-phase language.
The initial irritation phase from topical retinoids can include dryness.
Provided label excerpts provided do not include initial irritation-phase details.
The initial irritation phase from topical retinoids can include redness.
Provided label excerpts provided do not include initial irritation-phase details.
The initial irritation phase from topical retinoids can include peeling.
Provided label excerpts provided do not include initial irritation-phase details.
If skin becomes too irritated from Fabior, a prescriber may recommend reducing how often it is used or temporarily pausing treatment.
Provided label excerpts provided do not include specific prescriber adjustment guidance.
Fabior side effects are more likely when skin is sensitive.
Provided label excerpts provided do not include risk modifiers like 'sensitive skin'.
Fabior side effects are more likely during early treatment.
Provided label excerpts provided do not include timing frequency language for side effects.
Fabior side effects are more likely when used too frequently.
Provided label excerpts provided do not include frequency-related risk statements.
People with eczema or compromised skin barriers may have more irritation from retinoids.
Provided label excerpts provided do not include this statement.
Using a thin layer of Fabior and applying it only to the affected area can reduce side effects.
Provided label excerpts provided do not include application technique counseling.
Following the exact dosing frequency prescribed for Fabior can reduce side effects.
Provided label excerpts provided do not include this counseling.
Moisturizing as directed can help with Fabior-related dryness/peeling.
Provided label excerpts provided do not include moisturizer counseling.
Avoid sun exposure and other skin-irritating products on treated areas unless a clinician approves.
Provided label excerpts provided do not include sun/irritant avoidance counseling.
Fabior (tazarotene) can cause similar retinoid-type irritation symptoms to other topical retinoids such as tretinoin.
Provided label excerpts provided do not include comparisons to other topical retinoids.
Stop using Fabior and seek medical help if symptoms suggest an allergic reaction.
Provided label excerpts provided do not include hypersensitivity/allergic reaction counseling.
Contradictions
Low
AI Statement
If pregnant, trying to become pregnant, or could become pregnant, Fabior should not be used unless a prescriber has explicitly determined it is appropriate and pregnancy prevention guidance is followed.
Label Reference
Section 4 and 8.1: FABIOR Foam 'is contraindicated in pregnancy' and 'contraindicated in females who are or may become pregnant.'
Important Omissions
Do not use in pregnancy is a contraindication; the response frames pregnancy-related use as possibly conditional on prescriber determination, which is not reflected in the contraindication language in provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The pregnancy-related portion includes mostly on-label fetal risk/contraindication messaging, but it also introduces an 'unless explicitly determined appropriate' conditional framing for a contraindication, which could increase patient misuse risk. Most other irritation/application statements are unsupported due to missing label excerpts, limiting audit certainty.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Pregnancy contraindication was softened into a conditional 'prescriber may determine appropriate' statement, and most non-pregnancy skin/adverse reaction and application guidance is not supported by the label excerpts provided.
Suggested Improvement
Align pregnancy messaging exactly with contraindication wording: contraindicated in pregnancy and in females who are or may become pregnant; include contraception/pregnancy test and instruct to stop if pregnancy occurs per label. For non-pregnancy claims (application-site reactions, irritation timing, and specific 'avoid applying to X' instructions), only state what is explicitly supported by the provided label text.